ARQT Sep 2024 15.000 call
| Previous close | 0.9000 |
| Open | 0.9000 |
| Bid | 0.0000 |
| Ask | 0.6000 |
| Strike | 15.00 |
| Expiry date | 2024-09-20 |
| Day's range | 0.9000 - 0.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | 166 |
ZacksAmgen's (AMGN) Uplizna Meets Study Goal for Rare Disease
Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.
ZacksAbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at least two lines of prior therapy.
GlobeNewswireArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 57,500 restricted stock units of Arcutis’ common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducem
